Melanoma's Silver Lining in Biotech Boom The recent surge of Iovance Biotherapeutics' (IOVA) stock price has been driven by the success of its treatment for advanced melanoma, Amtagvi.
However, beneath this surface lies a more nuanced story about the intersection of medicine and commerce.
A Breakthrough in Biotech Iovance Biotherapeutics' treatment, Amtagvi, has been hailed as a breakthrough in the fight against advanced melanoma.